 Connection
Breelyn Wilky to Treatment Outcome
This is a "connection" page, showing publications Breelyn Wilky has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.259 |
|
|
|
-
Subhawong TK, Feister K, Sweet K, Alperin N, Kwon D, Rosenberg A, Trent J, Wilky BA. MRI Volumetrics and Image Texture Analysis in Assessing Systemic Treatment Response in Extra-Abdominal Desmoid Fibromatosis. Radiol Imaging Cancer. 2021 07; 3(4):e210016.
Score: 0.074
-
Wilky BA. Immune checkpoint inhibitors: The linchpins of modern immunotherapy. Immunol Rev. 2019 07; 290(1):6-23.
Score: 0.064
-
Wilky BA, Rudek MA, Ahmed S, Laheru DA, Cosgrove D, Donehower RC, Nelkin B, Ball D, Doyle LA, Chen H, Ye X, Bigley G, Womack C, Azad NS. A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours. Br J Cancer. 2015 Jan 06; 112(1):24-31.
Score: 0.046
-
Kerr DA, Pinto A, Subhawong TK, Wilky BA, Schlumbrecht MP, Antonescu CR, Nielsen GP, Rosenberg AE. Pericytoma With t(7;12) and ACTB-GLI1 Fusion: Reevaluation of an Unusual Entity and its Relationship to the Spectrum of GLI1 Fusion-related Neoplasms. Am J Surg Pathol. 2019 12; 43(12):1682-1692.
Score: 0.016
-
Ramachandran I, Lowther DE, Dryer-Minnerly R, Wang R, Fayngerts S, Nunez D, Betts G, Bath N, Tipping AJ, Melchiori L, Navenot JM, Glod J, Mackall CL, D'Angelo SP, Araujo DM, Chow WA, Demetri GD, Druta M, Van Tine BA, Grupp SA, Abdul Razak AR, Wilky B, Iyengar M, Trivedi T, Winkle EV, Chagin K, Amado R, Binder GK, Basu S. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. J Immunother Cancer. 2019 10 24; 7(1):276.
Score: 0.016
-
Ramey SJ, Yechieli R, Zhao W, Kodiyan J, Asher D, Chinea FM, Patel V, Reis IM, Wang L, Wilky BA, Subhawong T, Trent JC. Limb-sparing surgery plus radiotherapy results in superior survival: an analysis of patients with high-grade, extremity soft-tissue sarcoma from the NCDB and SEER. Cancer Med. 2018 09; 7(9):4228-4239.
Score: 0.015
-
Sebio A, Wilky BA, Keedy VL, Jones RL. The current landscape of early drug development for patients with sarcoma in the immunotherapy era. Future Oncol. 2018 May; 14(12):1197-1211.
Score: 0.015
-
Sheth PJ, Del Moral S, Wilky BA, Trent JC, Cohen J, Rosenberg AE, Temple HT, Subhawong TK. Desmoid fibromatosis: MRI features of response to systemic therapy. Skeletal Radiol. 2016 Oct; 45(10):1365-73.
Score: 0.013
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|